|
This CME has expired.
|
|
Pain Report #5
|
|
Editorial Faculty Board
Veerainder Goli, MD, FAAPM
Medical Director, Pain Evaluation & Treatment Services and Assistant
Medical Director, Duke Pain & Palliative Program
Assistant Clinical Professor of Psychiatry; Assistant Clinical Professor of Anesthesiology
Chief, Neuropsychiatric Services
Duke University Medical Center
Rebecca S. Finley, PharmD, MS, FASHP
Chair and Associate Professor
Department of Pharmacy Practice and Pharmacy Administration
Associate Dean for Pharmacy
Philadelphia College of Pharmacy
|
Release Date: April 2003
Expiration Date for Credit: April 30, 2007
Reviewed: April 2006
Supported by an unrestricted educational grant from
Purdue Pharma L.P.
|
Accreditation Statement
The Dannemiller Memorial Educational Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
The Dannemiller Memorial Educational Foundation designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Provider approved by the California Board of Registered Nursing, Provider Number 4229, for 1 contact hour.
RNs outside California must verify with their licensing agency for approval of this course.
Target Audience
This educational program is intended for pain management physicians and nurses.
Needs Assessment
While there is an abundance of clinical guidelines for pain management, it has been shown that not all of the various therapies in practice for pain are based on solid evidence-based inquiry. For example, low back pain (LBP) management is reflective of a gap between clinical guidelines and actual practice, particularly in the primary care setting. Novel therapies are continuously being studied. Traditional therapeutic options for LBP include exercise, oral anti-inflammatory or analgesic medication, antidepressants, physical therapy and in severe cases, surgery. Evidence-based guidelines also continue to be established in other areas of pain management, such as the most recently published arthritis treatment guidelines from the American Pain Society. New guidelines merit review and exposure to providers in arthritis pain management. Altogether a different challenge is the management of pain in end-of-life environments such as the evidence-based options for the practitioner in the management of cancer pain. Accordingly, there is a need to educate pain management physicians and nurses on therapeutic options for pain.
Method Of Participation
This activity should take approximately 1 hour to complete. The participant should:
- Read the objectives and article.
- Take the post-test. The post-test can be accessed by clicking on the post-test icon that follows the presentation.
- Complete the online registration and evaluation.
- Participants who complete the post-test, evaluation and registration will be issued a CME/CE certificate which may be printed at their location. A database of certificates awarded online is maintained at the accrediting agency. No additional certificate will be mailed. Expiration date for credit is March 31, 2006.
*In the event you are unable to print the certificate, please submit the post-test and then email editor@dannemiller.com and a certificate will be mailed to you within two weeks.
Evaluation
The activity evaluation form provides each participant the opportunity to comment on the extent to which educational objectives were met, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and specific views on future needs. This form is part of the registration form.
Educational Content
This issue of the Pain Report for which CME/CE credit will be awarded will consist of four articles dealing with effective pain management from the basis of clinical management, and specifically evidence-based cancer pain, low back and arthritis pain management.
Faculty Disclosure
Dr. Goli discloses that he is a consultant for Novartis, Pfizer, Celgene and UCB Pharma. He has received funding for multi-center clinical trials from Merck, and is pending funding for investigator initiated studies from Celgene and UCB Pharma.
Dr. Finley discloses that she is a speaker for Purdue Pharma.
Unlabeled Use of Products
Dipyrone is not currently FDA approved for use in the United States.
Objectives
- Explain effective pain management from the basis of clinical evidence.
- Describe low back pain and evidence supported therapies.
- Describe the recently published evidence-based arthritis treatment guideline from the American Pain Society.
- Identify evidence-based cancer pain treatment options.
» Click Here To Begin This Article
|
|
